Am J Rhinol Allergy:MIR-17-5P在季节过敏性鼻炎病理中的作用研究

2019-01-23 AlexYang MedSci原创

作为最流行的鼻炎类型,过敏性鼻炎包括了季节过敏性鼻炎(SAR)和永久过敏性鼻炎。最近,有研究人员尝试阐释SAR的机制。研究人员从基因表达综合数据库中提取了基因芯片数据集GSE43523(包括了7个SAR鼻上皮细胞和5个非过敏性对照鼻上皮细胞)数据。基于limma包,研究人员对2个组进行差异表达分析来获得差异表达的基因(DEGs)。另外,研究人员对DEGs基因的功能进行了富集分析。结合Cytosca

作为最流行的鼻炎类型,过敏性鼻炎包括了季节过敏性鼻炎(SAR)和永久过敏性鼻炎。最近,有研究人员尝试阐释SAR的机制。

研究人员从基因表达综合数据库中提取了基因芯片数据集GSE43523(包括了7个SAR鼻上皮细胞和5个非过敏性对照鼻上皮细胞)数据。基于limma包,研究人员对2个组进行差异表达分析来获得差异表达的基因(DEGs)。另外,研究人员对DEGs基因的功能进行了富集分析。结合Cytoscape软件,研究人员对蛋白互作(PPI)网络进行了构建,并获得了一个显著的网络模块。研究人员还对转录因子靶标和miRNA靶标对进行了预测。研究发现,鼻炎和对照群体之间具有274个DEGs,包括了144个上调的基因和130个下调的基因。在建立了DEGs的PPI后,研究人员鉴定了一个显著的网络模块。在TF-miRNA靶标调控网络中,ABCA1, CPEB4, CD69, MIR-17-5P和CREB程度更高。更多的是,ABCA1和CD69在调控网络中均是MIR-17-5P的靶标。

最后,研究人员指出,CPEB4和CREB也许在SAR病理中是有作用的。另外,MIR-17-5P通过靶向ABCA1和CD69在SAR中也具有作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930678, encodeId=4a0219306e81f, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Nov 27 08:13:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329201, encodeId=ff87132920198, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468703, encodeId=aec91468e03cb, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047069, encodeId=3462204e0697d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 28 08:13:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
    2019-11-27 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930678, encodeId=4a0219306e81f, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Nov 27 08:13:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329201, encodeId=ff87132920198, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468703, encodeId=aec91468e03cb, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047069, encodeId=3462204e0697d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 28 08:13:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
    2019-01-25 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930678, encodeId=4a0219306e81f, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Nov 27 08:13:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329201, encodeId=ff87132920198, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468703, encodeId=aec91468e03cb, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047069, encodeId=3462204e0697d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 28 08:13:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
    2019-01-25 30397606
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930678, encodeId=4a0219306e81f, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Nov 27 08:13:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329201, encodeId=ff87132920198, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468703, encodeId=aec91468e03cb, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Fri Jan 25 12:13:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047069, encodeId=3462204e0697d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 28 08:13:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]

相关资讯

Int Arch Allergy Immunol:早年环境因素、IFN-γ甲基化模式和儿童过敏性鼻炎相互关系研究

虽然早期生活的风险因素能够影响过敏的风险,而该现象潜在的生物学机制仍旧不清楚。最近,有研究人员调查了是否儿童时期DNA甲基化能够奠定早期生活风险因素与过敏性鼻炎的相关性。研究总共包括了234名患者,年龄6岁。其中114名为AR患者(AR组),120名为健康对照(NAR组)。研究发现,在调整了一些可能的共混杂因素后,那些母亲患有过敏的儿童的AR的可能性要比那些母亲不患有过敏的儿童更高(OR = 5.

Medicine (Baltimore):针灸在过敏性鼻炎患者中的治疗效果研究

最近,有研究人员在舌下特异性过敏原免疫治疗(SASIT)的过敏性鼻炎(AR)患者中,回顾性的分析了针灸疗法作为一种附加的疗法(AAOT)对过敏性鼻炎患者的治疗效果。研究总共包括了120名符合研究标准的AR成年人患者。其中60名患者接受了AAOT和SASIT治疗,并作为治疗组,其他60名受试者只接受了SASIT治疗,并作为对照组。主要结果为AR症状,次级结果为通过鼻炎生活质量调查问卷(RQLQ)评估

Medicine (Baltimore):过敏性鼻炎与阻塞性睡眠呼吸暂停相关性元分析

过敏性鼻炎(AR)与阻塞性睡眠呼吸暂停(OSA)共存是临床实践上的一种常见现象。AR长久以来被认为是OSA的一种风险因子。然而,相关关系仍旧不完全清楚。因此,最近,有研究人员进行了元分析来评估睡眠障碍性呼吸(SDB/)OSA中AR的流行度以及它们之间的关系。元分析总共包括了44个已经报道的研究,总共有6086名参与者。对成年人来讲,SDB患者中AR的流行度为22.8%(95% CI, 15.0-3

Clin Exp Allergy:桦树花粉过敏皮下免疫治疗的效果和安全性评价

之前的桦树花粉皮下免疫治疗的临床试验一般进行1-2年的治疗周期,并且地理位置经常是单一的。最近,有研究人员在19个欧洲中心进行了为期3年的研究,他们评估了高剂量低致敏性桦树花粉过敏原皮下免疫治疗对那些确诊患有中度到重度季节过敏性鼻炎/鼻窦炎患者的治疗效果。研究包括了253名桦树花粉过敏患者,并随机分配到季节前安慰剂组(n=129)和积极治疗组(n=124)。研究发现,积极治疗vs安慰剂治疗患者的症

Int J Pediatr Otorhinolaryngol:早期家庭环境和疾病情况与过敏性鼻炎相关

尽管对过敏性鼻炎(AR)很关注,但是过敏性鼻炎相关的风险因子仍旧不清楚。最近,有研究人员分析了早期生活的家庭环境和疾病与AR之间的相关性。研究是一个案例-对照研究,包括了242名AR患者和258名健康对照。他们完成了调查问卷来调查早期生活的相关疾病情况、家族过敏历史和家庭环境因素。研究人员调查了与AR相关的40个风险因素并进行了卡方检验和逻辑回归分析。研究发现,母亲患的疾病(比如牙周炎,慢性鼻炎,

Int J Pediatr Otorhinolaryngol:季节性过敏性鼻炎中,DNA甲基化模式鉴定

最近,有研究人员鉴定了季节过敏性鼻炎中,明显的DNA甲基化模式。研究人员从ArrayExpress数据库中获得了E-GEOD-5022的甲基化概况,并根据甲基化数据对差异共甲基化网络(DCN)进行了构建。从DCN中,研究人员鉴定了多重差异化的模式(M-DMs)。研究人员还将明显的模式定位到具体的途径中,从而鉴定富集的途径。最后,研究人员指出,在DCN中,共鉴定了16个种子基因,并利用这16个种子基